Kalaris Therapeutics, Inc. (KLRS) stock
KLRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.43−0.03 (-2.05%)
Close on Nov 17, 2026Market cap $34.04MP/E –Yield –
Kalaris Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Kalaris Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $32.87M, down 39.5% year over year. For fiscal 2025 it was $30.75M, down 31.7% from the year before. The highest annual figure on record is $133.07M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $30.75M | -31.7% |
| FY2024 | Dec 31, 2024 | $45.04M | -66.2% |
| FY2023 | Dec 31, 2023 | $133.07M | +11.9% |
| FY2022 | Dec 31, 2022 | $118.87M | -1.5% |
| FY2021 | Dec 31, 2021 | $120.74M | +143.1% |
| FY2020 | Dec 31, 2020 | $49.66M | +205.7% |
| FY2019 | Dec 31, 2019 | $16.25M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $9.02M | +6.8% |
| Q1 FY2026 | Mar 31, 2026 | $7.57M | +25.6% |
| Q4 FY2025 | Dec 31, 2025 | $7.16M | +85.9% |
| Q3 FY2025 | Sep 30, 2025 | $9.13M | -74.7% |
| Q2 FY2025 | Jun 30, 2025 | $8.44M | +162.8% |
| Q1 FY2025 | Mar 31, 2025 | $6.03M | +207.5% |
| Q4 FY2024 | Dec 31, 2024 | $3.85M | -88.5% |
| Q3 FY2024 | Sep 30, 2024 | $36.02M | +5.5% |
| Q2 FY2024 | Jun 30, 2024 | $3.21M | -90.8% |
| Q1 FY2024 | Mar 31, 2024 | $1.96M | -93.6% |
| Q4 FY2023 | Dec 31, 2023 | $33.37M | +17.4% |
| Q3 FY2023 | Sep 30, 2023 | $34.16M | +13.8% |
| Q2 FY2023 | Jun 30, 2023 | $34.82M | +11.0% |
| Q1 FY2023 | Mar 31, 2023 | $30.72M | +5.7% |
| Q4 FY2022 | Dec 31, 2022 | $28.42M | -31.7% |
| Q3 FY2022 | Sep 30, 2022 | $30.00M | -9.2% |
| Q2 FY2022 | Jun 30, 2022 | $31.38M | +22.2% |
| Q1 FY2022 | Mar 31, 2022 | $29.07M | +42.5% |
| Q4 FY2021 | Dec 31, 2021 | $41.60M | +148.3% |
| Q3 FY2021 | Sep 30, 2021 | $33.06M | +92.4% |
| Q2 FY2021 | Jun 30, 2021 | $25.68M | +189.0% |
| Q1 FY2021 | Mar 31, 2021 | $20.39M | +198.2% |
| Q4 FY2020 | Dec 31, 2020 | $16.76M | +150.6% |
| Q3 FY2020 | Sep 30, 2020 | $17.18M | +203.8% |
| Q2 FY2020 | Jun 30, 2020 | $8.89M | +222.5% |
| Q1 FY2020 | Mar 31, 2020 | $6.84M | – |
| Q4 FY2019 | Dec 31, 2019 | $6.69M | – |
| Q3 FY2019 | Sep 30, 2019 | $5.66M | – |
| Q2 FY2019 | Jun 30, 2019 | $2.76M | – |
See a number that looks wrong?